Compare Bristol-Myers Squibb Co (BMY) vs Raytheon Technologies Corp (RTX) Price & Performance

Bristol-Myers Squibb CoTrade

Raytheon Technologies CorpTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Raytheon Technologies Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $132.45B), while Raytheon Technologies Corp trades at $223.28 (market cap $302.06B). The key difference: Raytheon Technologies Corp is far larger — about 2.3× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.

	BMY	RTX
Market Cap	$132.45B	$302.06B
Sector	Health	Industrials
52-Week High	$65.89	$224.12
52-Week Low	$42.60	$151.75
Enterprise Value	$166.44B	$332.61B
Dividend Yield	3.89%	1.3%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

No Aura AI signal available yet.

Raytheon Technologies Corp

RTX trades at $223.86, up 0.37% today, with a bullish technical signal and strong analyst consensus of 17 buys and a $233.14 price target. Recent earnings beats and a $515 million Navy radar contract (PRNewsWire, June 3, 2026) highlight operational momentum. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.28%, though a P/E of 39.46 suggests premium valuation.

The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation and geopolitical dependencies. Cash flow trends show strengthening operations, supporting dividend payments and strategic investments.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BMY

View details →

RTX

U.S. Army awards $472M contract to Collins Aerospace for CH-47 Chinook avionics upgradesPRNewsWire · 1 day agoBullish Raytheon wins $745M contract to produce advanced SM-3 IIA missile interceptors for U.S. and alliesPRNewsWire · 2 days agoBullish Raytheon and CET demo HADALUS, a low-cost autonomous undersea vehicle with launch capabilities.PRNewsWire · 2 days agoBullish View details →

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.